Almonertinib
- Generic Name
- Almonertinib
- Drug Type
- Small Molecule
- Chemical Formula
- C30H35N7O2
- CAS Number
- 1899921-05-1
- Unique Ingredient Identifier
- T4RS462G19
- Background
Almonertinib is a third-generation EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing and T790M resistance mutations. It is being investigated against advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC).
- Indication
1.用于既往经表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）治疗时或治疗后出现疾病进展，并且经检测确认存在EGFR T790M 突变阳性的局部晚期或转移性非小细胞肺癌成人患者的治疗。
2.用于表皮生长因子受体（EGFR）敏感突变阳性局部晚期或转移性非小细胞肺癌（NSCLC）患者一线治疗。
Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC
- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- Radiation: Stereotactic Radiotherapy(SRT) or Stereotactic Radiosurgery(SRS) or Whole-Brain Radiotherapy(WBRT)
- First Posted Date
- 2021-05-27
- Last Posted Date
- 2021-06-02
- Lead Sponsor
- Chongqing University Cancer Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT04905550
- Locations
- 🇨🇳
Chongqing University Cancer Hospital, Chongqing, Chongqing, China
Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04882345
Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2021-05-03
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 232
- Registration Number
- NCT04870190
MRD Guiding Treatment After Almonertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model.
- First Posted Date
- 2021-04-12
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 192
- Registration Number
- NCT04841811
- Locations
- 🇨🇳
Guangdong Lung cancer institute, Guangzhou, Guangdong, China
Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 63
- Registration Number
- NCT04808752
- Locations
- 🇨🇳
Cancer Hospital Affiliated to University of Chinese Academy of Sciences, Hangzhou, Zhejiang, China
Almonertinib Combined With Pyrotinib in the Treatment of Advanced NSCLC Patients With HER-2 Amplification/Mutation After EGFR-TKI Resistance
- First Posted Date
- 2021-03-08
- Last Posted Date
- 2021-03-08
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 36
- Registration Number
- NCT04785729
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, GuangZhou, Guang Dong, China
Almonertinib for Advanced NSCLC Patients With Rare Mutations in EGFR
- First Posted Date
- 2021-03-08
- Last Posted Date
- 2021-03-08
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 40
- Registration Number
- NCT04785742
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guang Dong, China
A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)
- Conditions
- Leptomeningeal MetastasisNSCLCBrain Metastases
- Interventions
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2021-08-31
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04778800
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection
- Conditions
- Non-small Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 606
- Registration Number
- NCT04762459
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanchang University, Nanchang, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences,Shenzhen Center, Shenzhen, China
Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2020-12-29
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Target Recruit Count
- 192
- Registration Number
- NCT04687241
- Locations
- 🇨🇳
Jilin Province Cancer Hospital, Changchun, Jilin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.